KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360).

Tiziana Comito, Mauro Loi, Ciro Franzese, Elena Clerici, Davide Franceschini, Marco Badalamenti, Maria Ausilia Teriaca, Lorenza Rimassa, Vittorio Pedicini, Dario Poretti, Luigi Alessandro Solbiati, Guido Torzilli, Roberto Ceriani, Ana Lleo, Alessio Aghemo, Armando Santoro, Marta Scorsetti

Curr Oncol 29(11) 8802-8813

PMID36421345
PMCIDPMC9689962
DOI10.3390/curroncol29110692
发表日期2022-11-24
入排依据:The record is a randomized Phase III oncology trial with human patients and time-to-event efficacy endpoints (local control, PFS, OS). However, the intervention compared is stereotactic body radiotherapy (SBRT) versus transcatheter arterial (chemo-)embolization (TAE/TACE). TACE is a procedure involving embolization and may include chemotherapy, but the trial is fundamentally comparing a radiation technique to an embolization procedure. The abstract does not specify a standardized drug regimen as the intervention; it focuses on the procedural modality. Therefore, it does not meet the requirement for a drug-containing intervention.
摘要

摘要

Background: Hepatocellular carcinoma (HCC) is the most frequent liver malignancy and a leading cause of cancer death in the world. In unresectable HCC patients, transcatheter arterial (chemo-) embolization (TAE/TACE) has shown a disease response in 15-55% of cases. Though multiple TAE/TACE courses can be administered in principle, Stereotactic Body Radiotherapy (SBRT) has emerged as an alternative option in the case of local relapse following multiple TAE/TACE courses. Methods: This is a single-center, prospective, randomized, controlled, parallel-group superiority trial of SBRT versus standard TAE/TACE for the curative treatment of the intermediate stage of HCC after an incomplete response following TAE/TACE (NCT02323360). The primary endpoint is 1-year local control (LC): 18 events were needed to assess a 45% difference (HR: 0.18) in favor of SBRT. The secondary endpoints are 1-year Progression-Free Survival (PFS), Distant Recurrence-Free Survival (DRFS), Overall Survival (OS) and the incidence of acute and late complications. Results: At the time of the final analysis, 40 patients were enrolled, 19 (49%) in the TAE/TACE arm and 21 (51%) in the SBRT arm. The trial was prematurely closed due to slow accrual. The 1- and 2-year LC rates were 57% and 36%. The use of SBRT resulted in superior LC as compared to TAE/TACE rechallenge (median not reached versus 8 months, p = 0.0002). PFS was 29% and 16% at 1 and 2 years, respectively. OS was 86% and 62% at 1 year and 2 years, respectively. In the TAE arm, PFS was 13% and 6% at 1 and 2 years, respectively. In the SBRT arm, at 1 and 2 years, PFS was 37% and 21%, respectively. OS at 1 and 2 years was 75% and 64% in the SBRT arm and 95% and 57% in the TACE arm, respectively. No grade >3 toxicity was recorded. Conclusions: SBRT is an effective treatment option in patients affected by inoperable HCC experiencing an incomplete response following ≥1 cycle of TAE/TAC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。